BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32500223)

  • 1. Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis-a dangerous disease.
    Jin Z; Wang Y; Wei N; Wang Z
    Ann Hematol; 2020 Jul; 99(7):1575-1581. PubMed ID: 32500223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.
    Kanakry JA; Li H; Gellert LL; Lemas MV; Hsieh WS; Hong F; Tan KL; Gascoyne RD; Gordon LI; Fisher RI; Bartlett NL; Stiff P; Cheson BD; Advani R; Miller TP; Kahl BS; Horning SJ; Ambinder RF
    Blood; 2013 May; 121(18):3547-53. PubMed ID: 23386127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
    Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
    Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemoperfusion for Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis.
    Tatara R; Sato M; Fujiwara S; Oh I; Muroi K; Ozawa K; Nagai T
    Intern Med; 2014; 53(20):2365-8. PubMed ID: 25318804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
    J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignancy-associated hemophagocytic lymphohistiocytosis in children: a 10-year experience of a single pediatric hematology center.
    Huang Z; Jia Y; Zuo Y; Wu J; Lu A; Zhang L
    Hematology; 2020 Dec; 25(1):389-399. PubMed ID: 33161882
    [No Abstract]   [Full Text] [Related]  

  • 7. Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma.
    Park JH; Yoon DH; Kim S; Park JS; Park CS; Sung H; Lee SW; Huh J; Suh C
    Ann Hematol; 2016 Apr; 95(5):801-8. PubMed ID: 26883027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study.
    Li B; Guo J; Li T; Gu J; Zeng C; Xiao M; Zhang W; Li Q; Zhou J; Zhou X
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e198-e205. PubMed ID: 33303420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH.
    Shamriz O; Kumar D; Shim J; Briones M; Quarmyne MO; Chonat S; Lucas L; Edington H; White MH; Mahajan A; Park S; Chandrakasan S
    J Clin Immunol; 2021 Oct; 41(7):1582-1596. PubMed ID: 34173902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte-depleted Hodgkin lymphoma complicating hemophagocytic lymphohistiocytosis as an initial manifestation: a case report and review of the literature.
    Hagihara M; Inoue M; Hua J; Iwaki Y
    Intern Med; 2012; 51(21):3067-72. PubMed ID: 23124152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Shiraishi A; Ohga S; Doi T; Ishimura M; Takimoto T; Takada H; Miyamoto T; Abe Y; Hara T
    Pediatr Blood Cancer; 2012 Aug; 59(2):265-70. PubMed ID: 22183955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature.
    Hu S; Bansal P; Lynch D; Rojas Hernandez CM; Dayao Z
    J Med Case Rep; 2016 Dec; 10(1):365. PubMed ID: 27998299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
    Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary.
    McLaughlin M; Kelsey TW; Wallace WH; Anderson RA; Telfer EE
    Hum Reprod; 2017 Jan; 32(1):165-174. PubMed ID: 27923859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of immunochemotherapy and stem cell transplantation on EBV-associated hemophagocytic lymphohistiocytosis in children: a systematic review and meta analysis.
    Qin Q; Xie Z; Shen Y; Yang S; Liu C; Huang Z; Xu J; Al J; Shen K
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):672-8. PubMed ID: 22774410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group.
    Kogawa K; Sato H; Asano T; Ohga S; Kudo K; Morimoto A; Ohta S; Wakiguchi H; Kanegane H; Oda M; Ishii E
    Pediatr Blood Cancer; 2014 Jul; 61(7):1257-62. PubMed ID: 24535916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment outcomes and prognostic analysis of 61 Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis].
    Zeng X; Wei N; Wang Y; Wang J; Zhang J; Wu L; Huang W; Gao Z; Pei R; Chen J; Jin Z; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):507-10. PubMed ID: 26134018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection.
    Meng GQ; Wang JS; Wang YN; Wei N; Wang Z
    Int Immunopharmacol; 2021 Jul; 96():107606. PubMed ID: 33826999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Li Z; Wang Y; Wang J; Zhang J; Wang Z
    Leuk Lymphoma; 2018 Jan; 59(1):77-84. PubMed ID: 28573910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-DEP regimen is effective as an initial therapy for adult EBV-HLH.
    Chen L; Wang J; Wang Z
    Ann Hematol; 2022 Nov; 101(11):2461-2470. PubMed ID: 36094533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.